Information de reference pour ce titreAccession Number: | 00078447-200310300-00011.
|
Author: | Kovar, M *,a; Mrkvan, T a; Strohalm, J b; Etrych, T b; Ulbrich, K b; Stastny, M a; Rihova, B a
|
Institution: | (a)Department of Immunology and Gnotobiology, Institute of Microbiology, Academy of Sciences of the Czech Republic, Videnska 1083, 142 20 Prague 4, Czech Republic (b)Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovsky Square 2, 162 06 Prague 6, Czech Republic
|
Title: | HPMA copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia.[Article]
|
Source: | Journal of Controlled Release. 92(3):315-330, October 2003.
|
Abstract: | : N-(2-Hydroxypropyl)methacrylamide (HPMA) copolymer carrier containing the anticancer drug doxorubicin and targeted with B1 monoclonal antibody (mAb) to BCL1 leukemia cells was synthesised and tested in vitro and in vivo. BCL1 leukemia growing in syngenic Balb/c mice was selected as a tumor model system. B1 mAb recognising the idiotype of surface IgM on BCL1 cells was used as a targeting moiety. Both B1 mAb and doxorubicin were conjugated to HPMA copolymer carrier by aminolysis through a tetrapeptidic Gly-Phe(D,L)-Leu-Gly spacer to ensure the intracellular delivery and controlled release of the drug. B1 mAb-targeted conjugate was shown to possess strictly tumor-specific binding capacity to target BCL1 cells in vitro. A similar conjugate, but containing human nonspecific Ig (HuIg) instead of B1 mAb, failed to bind to BCL1 cells. In vitro, B1 mAb-targeted conjugate demonstrated 40-fold higher cytotoxic effect than nontargeted or human nonspecific Ig-containing HPMA copolymer-bound doxorubicin. Conjugate targeted with B1 mAb was also shown to bind to target BCL1 cells in vivo. B1 mAb-targeted conjugate was shown to be more efficient in the treatment of established BCL1 leukemia than free doxorubicin, nontargeted and human nonspecific Ig-containing conjugate. Antibody-targeted polymeric drugs are thus promising conjugates for cancer treatment.
(C) 2003Elsevier, Inc.
|
Author Keywords: | HPMA copolymer; Doxorubicin; Drug targeting; Monoclonal antibody; Tumor-specific antigen.
|
References: | [1] A. Allen, The cardiotoxicity of chemotherapeutic drugs. Semin. Oncol 19 (1992) 529-542.
[2] P. Rossmann, B. Rihova, J. Strohalm, K. Ulbrich, Morphology of rat kidney and thymus after native and antibody-coupled cyclosporin A application (reduced toxicity of targeted drug). Folia Microbiol 42 (1997) 277-287.
[3] M. St'astny, J. Strohalm, K. Ulbrich, B. Rihova, Pharmacokinetics and specificity of targeting by antibodies of HPMA conjugates of doxorubicin in vitro and in vivo. Immunol. Lett 56 (1997) 489.
[4] B. Rihova, K. Veres, L. Fornusek, K. Ulbrich, J. Strohalm, V. Vetvicka, M. Bilej, J. Kopecek, Action of the polymeric prodrugs based on N-(2-hydroxypropyl)methacrylamide: 2. Body distribution and T cell accumulation of 125 DNM. J. Control. Release 10 (1989) 37-49.
[5] J.J. Shiah, Y. Sun, C.M. Peterson, J. Kopecek, Biodistribution of free and N-(2-hydroxypropyl)methacrylamide copolymer-bound mesochlorin e(6) and adriamycin in nude mice bearing human ovarian carcinoma OVCAR-3 xenografts. J. Control. Release 61 (1999) 145-157.
[6] B. Rihova, J. Strohalm, K. Kubackova, M. Jelinkova, L. Rozprimova, M. Sirova, D. Plocova, T. Mrkvan, M. Kovar, J. Pokorna, T. Etrych, K. Ulbrich, Drug-HPMA-huIg conjugates effective against human solid cancer. Adv. Exp. Med. Biol. (2003) 125-143.
[7] P.A. Vasey, S.B. Kaye, R. Morrison, C. Twelves, P. Wilson, R. Duncan, A.H. Thomson, L.S. Murray, T.E. Hilditch, T. Murray, S. Burtles, D. Fraier, E. Frigerio, J. Cassidy, Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates, Cancer Research Campaign Phase I/II Committee. Clin. Cancer Res 5 (1999) 83-94.
[8] B. Rihova, J. Strohalm, K. Kubackova, M. Jelinkova, O. Hovorka, M. Kovar, D. Plocova, M. Sirova, M. St'astny, L. Rozprimova, K. Ulbrich, Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs. J. Control. Release 78 (2002) 97-114.
[9] H. Maeda, J. Wu, T. Sawa, Y. Matsumura, K. Hori, Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65 (2000) 271-284.
[10] Y. Noguchi, J. Wu, R. Duncan, J. Strohalm, K. Ulbrich, T. Akaike, H. Maeda, Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res 89 (1998) 307-314.
[11] Y. Shoenfeld, P. Fishman, Gamma-globulin inhibits tumor spread in mice. Int. Immunol 11 (1999) 1247-1252.
[12] B. Rihova, M. Jelinkova, J. Strohalm, M. St'astny, O. Hovorka, D. Plocova, M. Kovar, L. Draberova, K. Ulbrich, Antiproliferative effect of a lectin- and anti-Thy-1.2 antibody-targeted HPMA copolymer-bound doxorubicin on primary and metastatic human colorectal carcinoma and on human colorectal carcinoma transfected with the mouse Thy-1.2 gene. Bioconjug. Chem 11 (2000) 664-673.
[13] R. Duncan, P. Kopeckova, J. Strohalm, I.C. Hume, J.B. Lloyd, J. Kopecek, Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers: II. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia. Br. J. Cancer 57 (1988) 147-156.
[14] B. Rihova, Antibody-targeted polymer-bound drugs. Folia Microbiol 40 (1995) 367-384.
[15] V. Omelyanenko, P. Kopeckova, C. Gentry, J.G. Shiah, J. Kopecek, HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates: 1. Influence of the method of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro. J. Drug Target 3 (1996) 357-373.
[16] V. Omelyanenko, C. Gentry, P. Kopeckova, J. Kopecek, HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates: II. Processing in epithelial ovarian carcinoma cells in vitro. Int. J. Cancer 75 (1998) 600-608.
[17] M.V. Pimm, A.C. Perkins, R. Duncan, K. Ulbrich, Targeting of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate to the hepatocyte galactose-receptor in mice: visualisation and quantification by gamma scintigraphy as a basis for clinical targeting studies. J. Drug Target 1 (1993) 125-131.
[18] L.W. Seymour, K. Ulbrich, S.R. Wedge, I.C. Hume, J. Strohalm, R. Duncan, N-(2-Hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor: pharmacokinetics in DBA2 mice. Br. J. Cancer 63 (1991) 859-866.
[19] M. Wirth, A. Fuchs, M. Wolf, B. Ertl, F. Gabor, Lectin-mediated drug targeting: preparation, binding characteristics, and antiproliferative activity of wheat germ agglutinin conjugated doxorubicin on Caco-2 cells. Pharm. Res 15 (1998) 1031-1037.
[20] S. Wroblewski, B. Rihova, P. Rossmann, T. Hudcovicz, Z. Rehakova, P. Kopeckova, J. Kopecek, The influence of a colonic microbiota on HPMA copolymer lectin conjugates binding in rodent intestine. J. Drug Target 9 (2001) 85-94.
[21] B. Rihova, J. Strohalm, K. Hoste, M. Jelinkova, O. Hovorka, L. Kovar, D. Plocova, M. Sirova, M. St'astny, E. Schacht, K. Ulbrich, Immunoprotective therapy with targeted anticancer drugs. Macromol. Symp 172 (2001) 21-28.
[22] M. Kovar, J. Strohalm, K. Ulbrich, B. Rihova, In vitro and in vivo effect of HPMA copolymer-bound doxorubicin targeted to transferrin receptor of B-cell lymphoma 38C13. J. Drug Target 10 (2002) 23-30.
[23] P.A. Flanagan, R. Duncan, B. Rihova, Immunogenicity of protein-N-(2-hydroxypropyl)methacrylamide copolymer conjugates in A/J and B10 mice. J. Bioact. Compat. Polym. (1990) 151-166.
[24] K. Ulbrich, V. Subr, J. Strohalm, D. Plocova, M. Jelinkova, B. Rihova, Polymeric drugs based on conjugates of synthetic and natural macromolecules: I. Synthesis and physico-chemical characterisation. J. Control. Release 64 (2000) 63-79.
[25] B. Rihova, M. Bilej, V. Vetvicka, K. Ulbrich, J. Strohalm, J. Kopecek, R. Duncan, Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin. Immunogenicity, and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro. Biomaterials 10 (1989) 335-342.
[26] P. Rejmanova, J. Pohl, M. Baudys, Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B. Makromol. Chem 184 (1983) 2009-2020.
[27] J. Kopecek, P. Rejmanova, V. Chytry, Polymers containing enzymatically degradable bonds: 1. Chymotrypsin catalyzed hydrolysis of p-nitroanilides of phenylalanine and tyrosine attached to side-chains of copolymers of N-(2-hydroxypropyl)methacrylamide. Makromol. Chem 182 (1981) 799-809.
[28] V. Subr, J. Strohalm, K. Ulbrich, R. Duncan, I.C. Hume, Polymers containing enzymatically degradable bonds: XII. Effect of spacer structure on the rate of release of daunomicin from poly[N-(2-hydroxypropyl)-methacrylamide] copolymer drug carriers in vitro and antitumour activity measured in vivo. J. Control. Release 18 (1992) 123-132.
[29] M. St'astny, D. Plocova, T. Etrych, M. Kovar, K. Ulbrich, B. Rihova, HPMA-hydrogels containing cytostatic drugs. Kinetics of the drug release and in vivo efficacy. J. Control. Release 81 (2002) 101-111.
[30] J. Brissinck, C. Demanet, M. Moser, O. Leo, K. Thielemans, Treatment of mice bearing BCL1 lymphoma with bispecific antibodies. J. Immunol 147 (1991) 4019-4026.
[31] M. Kovar, J. Strohalm, T. Etrych, K. Ulbrich, B. Rihova, Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect. Bioconjug. Chem 13 (2002) 206-215.
[32] K.B. O'Hare, R. Duncan, J. Strohalm, K. Ulbrich, P. Kopeckova, Polymeric drug-carriers containing doxorubicin and melanocyte-stimulating hormone: in vitro and in vivo evaluation against murine melanoma. J. Drug Target 1 (1993) 217-229.
[33] B. Rihova, J. Kopecek, Biological properties of targetable poly[N-(2-hydroxypropyl)methacrylamide]-antibody conjugates. J. Control. Release 2 (1985) 289-310.
[34] B. Rihova, J. Kopecek, P. Kopeckova-Rejmanova, J. Strohalm, D. Plocova, H. Semoradova, Bioaffinity therapy with antibodies and drugs bound to soluble synthetic polymers. J. Chromatogr 376 (1986) 221-233.
[35] J.G. Shiah, Y. Sun, C.M. Peterson, R.C. Straight, J. Kopecek, Antitumor activity of N-(2-hydroxypropyl) methacrylamide copolymer-mesochlorine e6 and adriamycin conjugates in combination treatments. Clin. Cancer Res 6 (2000) 1008-1015.
[36] S. Slavin, S. Strober, Spontaneous murine B-cell leukaemia. Nature 272 (1978) 624-626.
[37] L.W. Seymour, K. Ulbrich, J. Strohalm, J. Kopecek, R. Duncan, The pharmacokinetics of polymer-bound adriamycin. Biochem. Pharmacol 39 (1990) 1125-1131.
[38] T.K. Yeung, J.W. Hopewell, R.H. Simmonds, L.W. Seymour, R. Duncan, O. Bellini, M. Grandi, F. Spreafico, J. Strohalm, K. Ulbrich, Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat. Cancer Chemother. Pharmacol 29 (1991) 105-111.
[39] J.M. Lu, C.M. Peterson, J. Guo-Shiah, Z.W. Gu, C.A. Peterson, R.C. Straight, J. Kopecek, Cooperativity between free and N-(2-hydroxypropyl) methacrylamide copolymer bound adriamycin and meso-chlorin e6 monoethylene diamine induced photodynamic therapy in human epithelial ovarian carcinoma in vitro. Int. J. Oncol 15 (1999) 5-16.
[40] B. Rihova, M. Jelinkova, J. Strohalm, V. Subr, D. Plocova, O. Hovorka, M. Novak, D. Plundrova, Y. Germano, K. Ulbrich, Polymeric drugs based on conjugates of synthetic and natural macromolecules: II. Anti-cancer activity of antibody or (Fab')(2)-targeted conjugates and combined therapy with immunomodulators. J. Control. Release 64 (2000) 241-261.
|
Language: | English.
|
Document Type: | Article.
|
Journal Subset: | Pharmacology.
|
ISSN: | 0168-3659
|
DOI Number: | https://dx.doi.org/10.1016/S0168...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|